A previously poor prognostic cancer type, iCCA is now known to show distinctive molecular aberrations and targetable molecular changes; most notable are translocations of fibroblast growth factor receptor 2 (FGFR2) and, isocitrate dehydrogenase (IDH) 1/2 mutations. The gene discussed is FGFR2; the disease is cancer.